Five Prime Therapeutics Inc (FPRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Five Prime Therapeutics Inc (FPRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH136045D
  • |
  • Pages: 85
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Five Prime Therapeutics Inc (Five Prime) is a clinical state biopharmaceutical company focusing on the research and development of novel treatments for cancer and inflammatory disorders. The company's developmental pipeline is based on the discovery platform and library of therapeutic proteins. The company's pipeline products include cabiralizumab,; FPA144; FPT-155; FPA-150; FPA-151; Tim- 3 antibody; novel I-O biologics and I-O antibody for treating various forms of cancer. Five Prime has also developed proprietary protein screening technologies and rapid in vivo protein production system to identify new targets for protein therapeutics. The company has development collaborations with companies such as Bristol-Myers Squibb, GlaxoSmithKline, Zai Lab, Galaxy Biotech, BioWa-Lonza and UCB Pharma. Five Prime is headquartered in South San Francisco, California, the US.

Five Prime Therapeutics Inc (FPRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note : Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Five Prime Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Five Prime Therapeutics Raises USD 10 Million In Venture Financing 13

Partnerships 14

Five Prime Therapeutics Enters into Partnership with Roche 14

Five Prime Therapeutics Enters into Agreement with University of Minnesota Medical School 15

Vaccinex Enters into Drug Discovery Agreement with Five Prime Therapeutics 16

Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics for Opdivo and FPA008 17

Five Prime Therapeutics Enters Into Research Agreement With Adimab 20

UCB Enters Into Research Agreement With Five Prime Therapeutics 21

Five Prime Therapeutics Amends Agreement With GlaxoSmithKline 22

Licensing Agreements 23

UCB Enters into Licensing Agreement with Five Prime Therapeutics 23

Zai Lab Enters into Licensing Agreement with Five Prime Therapeutics 24

Ablexis Enters into Licensing Agreement with Five Prime Therapeutics 25

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 26

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 27

Five Prime Therapeutics Expands Licensing Agreement with Bristol-Myers Squibb 28

Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 30

Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 32

ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 33

Equity Offering 35

Five Prime Therapeutics Raises USD115 Million in Public offering of Shares 35

Five Prime Therapeutics Raises USD84.3 Million in Public Offering of Shares 37

Five Prime Therapeutics Completes Private Placement Of Shares For USD 21 Million 39

Five Prime Therapeutics Completes Public Offering Of Shares For USD 43 Million 40

Five Prime Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option Of IPO For USD 71.8 Million 42

Five Prime Therapeutics Inc-Key Competitors 44

Five Prime Therapeutics Inc-Key Employees 45

Five Prime Therapeutics Inc-Locations And Subsidiaries 46

Head Office 46

Recent Developments 47

Financial Announcements 47

Aug 08, 2018: Five Prime Therapeutics announces second quarter 2018 financial results 47

May 08, 2018: Five Prime Therapeutics Reports First Quarter 2018 Financial Results 50

Feb 27, 2018: Five Prime Announces Fourth Quarter and Full Year 2017 Financial Results 52

Nov 06, 2017: Five Prime Announces Third Quarter 2017 Results and Provides Business Update 56

Aug 08, 2017: Five Prime Announces Second Quarter 2017 Results and Provides Business Update 58

May 04, 2017: Five Prime Announces First Quarter 2017 Results and Provides Business Update 62

Feb 23, 2017: Five Prime Announces Fourth Quarter and Full Year 2016 Financial Results 66

Corporate Communications 69

May 15, 2018: Five Prime Therapeutics Appoints Bryan Irving, Ph.D., as Chief Scientific Officer 69

Mar 13, 2018: Five Prime Therapeutics Announces Executive Change 70

Oct 23, 2017: Five Prime Therapeutics Announces Appointment of Aron Knickerbocker as CEO Effective January 1, 2018 71

Aug 17, 2017: Five Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research 72

Jun 21, 2017: Five Prime Therapeutics Announces Lewis T. Rusty Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018 73

May 15, 2017: Five Prime Welcomes Garry Nicholson to Board of Directors 74

Mar 20, 2017: Five Prime Therapeutics Announces Executive Changes 75

Product News 76

04/20/2017: Five Prime to Present Clinical Data on FPA144 at 2017 ASCO Annual Meeting 76

Clinical Trials 77

Jan 02, 2018: Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer 77

Nov 10, 2017: Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting 78

Oct 30, 2017: Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155 79

Oct 18, 2017: Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 80

Jul 17, 2017: Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development 81

Jun 03, 2017: Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 at 2017 ASCO Annual Meeting 82

Other Significant Developments 84

May 29, 2018: Five Prime Therapeutics Walks to End Pancreatic Cancer at PurpleStride San Francisco 2018 84

Appendix 85

Methodology 85

About GlobalData 85

Contact Us 85

Disclaimer 85

List of Figures

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Five Prime Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Five Prime Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Five Prime Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Five Prime Therapeutics Raises USD 10 Million In Venture Financing 13

Five Prime Therapeutics Enters into Partnership with Roche 14

Five Prime Therapeutics Enters into Agreement with University of Minnesota Medical School 15

Vaccinex Enters into Drug Discovery Agreement with Five Prime Therapeutics 16

Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics for Opdivo and FPA008 17

Five Prime Therapeutics Enters Into Research Agreement With Adimab 20

UCB Enters Into Research Agreement With Five Prime Therapeutics 21

Five Prime Therapeutics Amends Agreement With GlaxoSmithKline 22

UCB Enters into Licensing Agreement with Five Prime Therapeutics 23

Zai Lab Enters into Licensing Agreement with Five Prime Therapeutics 24

Ablexis Enters into Licensing Agreement with Five Prime Therapeutics 25

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 26

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 27

Five Prime Therapeutics Expands Licensing Agreement with Bristol-Myers Squibb 28

Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 30

Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 32

ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 33

Five Prime Therapeutics Raises USD115 Million in Public offering of Shares 35

Five Prime Therapeutics Raises USD84.3 Million in Public Offering of Shares 37

Five Prime Therapeutics Completes Private Placement Of Shares For USD 21 Million 39

Five Prime Therapeutics Completes Public Offering Of Shares For USD 43 Million 40

Five Prime Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option Of IPO For USD 71.8 Million 42

Five Prime Therapeutics Inc, Key Competitors 44

Five Prime Therapeutics Inc, Key Employees 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Five Prime Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 17970
Site License
USD 500 INR 35940
Corporate User License
USD 750 INR 53910

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com